2-deoxy-2-fluoro-D-[UL-13C6;UL-D7]glucose

2-deoxy-2-fluoro-D-[UL-13C6;UL-D7]glucose, also known as 2-FDG, is a radiolabeled glucose analogue commonly used in medical imaging techniques such as positron emission tomography (PET) scans. This molecule is structurally similar to glucose, but with a fluorine atom substituted for the hydroxyl group at the 2nd carbon position, and carbon-13 and deuterium isotopes incorporated into the molecule for imaging purposes. When administered intravenously, 2-FDG is taken up by cells in the body and metabolized like glucose. However, because it cannot be completely metabolized, it accumulates in cells that are using large amounts of glucose, such as cancer cells or areas of inflammation. PET scans can detect the radioactive decay of the isotopes incorporated into 2-FDG, allowing for visualization and quantification of these areas of high glucose metabolism. In addition to its use in medical imaging, 2-FDG has also been studied for its potential as a cancer treatment. By selectively targeting cancer cells and disrupting their metabolism, it may be possible to reduce tumor growth and improve patient outcomes. Overall, 2-deoxy-2-fluoro-D-[UL-13C6;UL-D7]glucose is a valuable tool in medical research and clinical practice for imaging and potentially treating cancer.